Evonik Boosts Methionine Production Efficiency with Major European Upgrade

Evonik Boosts Methionine Production Efficiency with Major European Upgrade

(IN BRIEF) Evonik is investing a low double-digit million euro sum to upgrade its European methionine Verbund in Antwerp and Wesseling, part of its global network for MetAMINO® (DL-methionine) production. The planned technical enhancements—such as a new process control system and an advanced bagging station—aim to improve process efficiency, reliability, and sustainability, while also reducing nitrogen, sulfur, and CO₂ emissions. To implement these upgrades, the facilities will undergo a partial shutdown for 8 to 10 weeks between May and July 2025, although existing contracts and supply agreements will remain unaffected. Dr. Dirk Hoehler emphasizes that this investment is essential for maintaining competitive advantage and ensuring supply security for customers, while also supporting the company’s commitment to sustainability under strict European standards. Evonik is uniquely positioned in the methionine market with its three global production hubs in Antwerp/Wesseling, Mobile, and Singapore, and its MetAMINO® product plays a crucial role in enhancing livestock production to meet the growing global demand for animal protein.

(PRESS RELEASE) ESSEN, 18-Mar-2025 — /EuropaWire/ — Evonik is set to further optimize its global production network for MetAMINO® (DL-methionine) through a technical upgrade of its European methionine Verbund located in Antwerp, Belgium, and Wesseling, Germany. This strategic investment, amounting to a low double-digit million euro sum, is aimed at significantly enhancing process efficiency, reliability, and sustainability across the production facilities. In order to implement these cutting-edge upgrades—including a new process control system and an advanced bagging station, along with various technical improvements designed to reduce nitrogen, sulfur, and CO₂ emissions—a partial shutdown of the facilities will be necessary for a period of 8 to 10 weeks, scheduled to occur between May and July 2025. Importantly, all existing contracts and supply agreements will continue to be honored throughout this transition.

Dr. Dirk Hoehler, head of the amino acids business within Evonik’s Animal Nutrition business line, explained, “We are continuously striving to boost the process efficiency, reliability, and sustainability of our three global methionine production hubs. This ongoing investment is critical not only for maintaining our competitive edge but also for ensuring the highest possible supply security for our customers. Reducing our ecological footprint is a key motivation for us, and we are fully committed to meeting the strictest European sustainability standards.”

Evonik stands alone as the only global methionine producer operating three world-scale production hubs—in Antwerp/Wesseling, Mobile (Alabama, USA), and Singapore—serving the rapidly growing global feed markets. In recent years, the company has already invested over €200 million to expand its facilities in Singapore and to integrate backward its methionine production in Mobile. MetAMINO® is essential in livestock production, contributing to the health, efficiency, and sustainability of animal nutrition. Through its science-based approach, Evonik’s Animal Nutrition business line develops innovative products, services, and system solutions that help meet the increasing global demand for healthy, high-quality, and affordable animal protein.

About Evonik
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.2 billion and an operating profit (adjusted EBITDA) of €2,1 billion in 2024. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.76 billion in 2024 with more than 5,500 employees.

Disclaimer
In so far as forecasts or expectations are expressed in this release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Media contact:

Isabel Ramor
Head of Market Communications High Performance Polymers
Spoken languages: german , english
+49 2365 49-9878

Nina Peck
Head of Market Communications Smart Materials
Spoken languages: german , english
+49 201 177-2223

SOURCE:Evonik